UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16
or 15d-16
Under the Securities Exchange Act of 1934
For the Month of June, 2024
001-36000
(Commission File Number)
XTL Biopharmaceuticals Ltd.
(Exact name of Registrant as specified in its charter)
26 Ben-Gurion St.
Ramat Gan, Israel, 5112001
(Address of principal executive offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On June 12, 2024, XTL Biopharmaceuticals Ltd.
(the “Company”) announced that it will hold an Annual and Extraordinary General Meeting of Shareholders (the “Meeting”)
on July 22, 2024, at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman & Amit Gross., 7 Metsada St., B.S.R
Tower 4, 33 Floor, Bnei Brak, Israel. In connection with the Meeting, the Company furnishes the following documents:
| 1. | A
copy of the Notice and Proxy Statement with respect to the Company’s Meeting describing the proposals to be voted upon at the Meeting,
the procedure for voting in person or by proxy at the Meeting and various other details related to the Meeting, attached hereto as Exhibit
99.1; |
| 2. | A
form of Proxy Card whereby holders of ordinary shares of the Company may vote at the Meeting without attending in person, attached hereto
as Exhibit 99.2; and |
| 3. | A
form of Voting Instruction Card whereby holders of American Depositary Shares of the Company may vote at the Meeting without attending
in person, attached hereto as Exhibit 99.3. |
Exhibit Index
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
XTL BIOPHARMACEUTICALS LTD. |
| |
|
| Date: June 12, 2024 |
/s/ Shlomo Shalev |
| |
Shlomo Shalev |
| |
Chief Executive Officer |
3
Exhibit 99.1
NOTICE OF
ANNUAL AND EXTRAORDINARY GENERAL MEETING OF
SHAREHOLDERS
TO BE HELD ON JULY 22, 2024
To the shareholders of XTL Biopharmaceuticals
Ltd.:
Notice is hereby given that an Annual and Extraordinary
General Meeting (the “Annual Meeting”) of the shareholders of XTL Biopharmaceuticals Ltd. (the “Company”)
will be held at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman & Amit Gross, at 7 Metsada St., B.S.R Tower
4, Bnei Brak, Israel at 15:00 PM (Israel Time), on July 22, 2024.
The agenda of the Meeting will be as follows:
| |
1. |
To discuss the auditor’s report of our independent registered public accounting firm and audited financial statements for the year ended as of December 31, 2023. |
| |
|
|
| |
2. |
To re-appoint Somekh Chaikin, Certified Public Accountants in Israel and a member firm of KPMG as the Company’s independent auditors for the fiscal year ending December 31, 2024, and to authorize the Board of Directors, upon the recommendation of the Company’s audit committee (the “Audit Committee”), to determine the auditors’ remuneration to be fixed in accordance with the volume and nature of their services to the Company for such fiscal year. |
| |
|
|
| |
3. |
To re-elect Messrs. Alexander Rabinovitch, Shlomo Shalev, and Doron Turgeman to our Board of Directors, each for a term expiring at our next annual general meeting of shareholders (a separate vote for each director will be taken). Declaration of Directors Qualification is attached as Annex A hereto. |
| |
|
|
| |
4. |
To approve the terms and provisions of the acquisition of The Social Proxy Ltd. (“Social Proxy”), as further detailed in the Company’s Form 6-K dated June 5, 2024 (the “Transaction”) which includes (a) the issuance to the shareholders of Social Proxy such number of ADS’s of the Company which represent 44.6% of the issued and outstanding share capital of the Company and (b) the payment of US$430,000 in cash to the shareholders of Social Proxy. |
| |
|
|
| |
5. |
To approve that the Company shall enter into any and all agreement and other documents required in order to effect the Transaction and to authorize, empower and direct the Chief Executive Officer of the Company, in the name and on behalf of the Company, to take or cause to be taken any and all such further actions and to prepare, execute, deliver and file, or cause to be prepared, executed, delivered and filed any documents and such other reports, schedules, statements, consents, documents, agreements, certificates, undertakings in the name of and on behalf of the Company as he shall in his judgment, with the advice of counsel, determine to be necessary, proper or desirable to carry out fully the intent and purposes of the foregoing resolutions in order to consummate the transactions contemplated by the foregoing resolutions (the “Consummation”). |
| |
|
|
| |
6. |
To approve, conditional upon the Consummation of the Transaction, the election of Mr. Tal Klinger and Mr. Yair Redl to our Board of Directors each for a term expiring at our next annual general meeting of shareholders (a separate vote for each director will be taken). Declaration of Directors Qualification is attached as Annex B hereto. |
Only shareholders and holders of ordinary shares
represented by American Depositary Shares at the close of business on June 24, 2024 (the “Record Date”) are entitled
to notice of, and to vote at, the Annual Meeting and any adjournment or postponement thereof. You are cordially invited to attend the
Annual Meeting in person.
If you are unable to attend the Meeting in person,
you are requested to complete, date and sign the enclosed proxy and to return it promptly in the pre-addressed envelope provided. Shareholders
who attend the Annual Meeting may revoke their proxies and vote their shares in person.
Beneficial owners who hold ordinary shares through
members of the Tel Aviv Stock Exchange, or the TASE, may either vote their shares in person at the Annual Meeting by presenting a certificate
signed by the TASE Clearing House member through which the shares are held, which complies with the Israel Companies Regulations (Proof
of Ownership for Voting in General Meetings)-2000 as proof of ownership of the shares on the record date, or send such certificate along
with a duly executed proxy (in the form filed by us on MAGNA, the distribution site of the Israeli Securities Authority, at www.magna.isa.gov.il),
to us at 26 Ben-Gurion Street, Ramat Gan 5112001, Israel, Attention: Chief Executive Officer.
| |
By Order of the Board of Directors |
| |
|
| |
/s/ Shlomo Shalev |
| |
Shlomo Shalev |
| |
Chief Executive Officer |
| |
Dated: June 12, 2024 |
5 Ben-Gurion St.
Ramat Gan, Israel, 5112001
PROXY STATEMENT
FOR ANNUAL AND EXTRAORDINARY GENERAL MEETING
OF SHAREHOLDERS
TO BE HELD ON JULY 22, 2024
This Proxy Statement is furnished
to our holders of ordinary shares, par value NIS 0.1 per share and holders of our ordinary shares that are represented by American Depository
Shares, or ADSs, in connection with Annual and Extraordinary General Meeting of Shareholders (the “Annual Meeting”),
to be held on July 22, 2024, at 15:00 PM Israel time at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman &
Amit Gross, at 7 Metsada St., B.S.R Tower 4, Bnei Brak, Israel.
Throughout this Proxy Statement,
we use terms such as “XTL Biopharmaceuticals,” “XTL,” “we”, “us”, “our” and
the “Company” to refer XTL Biopharmaceuticals Ltd. and terms such as “you” and “your” to refer to
our shareholders and ADS holders.
Agenda Items
The agenda of the Annual Meeting
will be as follows:
1. To discuss the auditor’s
report of our independent registered public accounting firm and audited financial statements for the year ended December 31, 2023.
2. To appoint Somekh Chaikin,
Certified Public Accountants in Israel and a member firm of KPMG as the Company’s independent auditors for the fiscal year ending
December 31, 2024, and to authorize the Boad of Directors, upon the recommendation of the Audit Committee to determine the auditors’
remuneration to be fixed in accordance with the volume and nature of their services to the Company for such fiscal year.
3. To re-elect Mr. Alexander
Rabinovitch to our Board of Directors for a term expiring at our next annual general meeting of shareholders.
4. To re-elect Mr. Shlomo
Shalev to our Board of Directors for a term expiring at our next annual general meeting of shareholders.
5. To re-elect Mr. Doron Turgeman
to our Board of Directors for a term expiring at our next annual general meeting of shareholders.
6. To approve the terms and
provisions of the acquisition of The Social Proxy Ltd. (“Social Proxy”), as more fully detailed in the Company’s
Form 6-K dated June 5, 2024 (the “Transaction”) which includes (a) the issuance to the shareholders of Social Proxy
such number of ADS’s of the Company which represent 44.6% of the issued and outstanding share capital of the Company and (b) the
payment of US$430,000 in cash to the shareholders of Social Proxy.
7. To approve the consummation
of the Transaction by the Company and to authorize, empower and direct the Chief Executive Officer of the Company, in the name and on
behalf of the Company, to take or cause to be taken any and all such further actions he deems necessary for the completion of such consummation.
8. To approve, conditional
upon the consummation of the Transaction, the election of Mr. Tal Klinger to our Board of Directors for a term expiring at our next annual
general meeting of shareholders
9. To approve,
conditional upon the consummation of the Transaction, the election of Mr. Yair Redl to our Board of Directors for a term expiring at
our next annual general meeting of shareholders.
We currently are unaware of
any other matters that may be raised at the Annual Meeting. Should any other matters be properly raised at the Annual Meeting, the persons
designated as proxies shall vote according to their own judgment on those matters.
Board Recommendation
Our Board of Directors
unanimously recommends that you vote “FOR” each of agenda items 2 to 9.
Who Can Vote
Only shareholders and ADS
holders at the close of business on June 24, 2024 shall be entitled to receive notice of and to vote at the Annual Meeting.
How You Can Vote
You can vote your ordinary
shares by attending the Annual Meeting. If you do not plan to attend the Annual Meeting, the method of voting will differ for shares held
as a record holder, shares held in “street name” (through a Tel Aviv Stock Exchange, or TASE, member) and shares underlying
ADSs that you hold. Record holders of shares will receive proxy cards. Holders of shares in “street name” through a TASE member
will also vote via a proxy card, but through a different procedure (as described below). Holders of ADSs (whether registered in their
name or in “street name”) will receive voting instruction cards in order to instruct their banks, brokers or other nominees
on how to vote.
Shareholders of Record
If you are a shareholder of
record, you can submit your vote by completing, signing and submitting a proxy card, which has been published at www.magna.isa.gov.il,
to the Company’s office at 5 Ben-Gurion Street, Ramat Gan 5112001, Israel.
Please follow the instructions
on the proxy card.
Shareholders Holding in
“Street Name” through the TASE
If you hold ordinary shares
in “street name,” that is, through a bank, broker or other nominee that is admitted as a member of the TASE, your shares will
only be voted if you provide instructions to the bank, broker or other nominee as to how to vote, or if you attend the Annual Meeting
in person.
If voting by mail, you must
sign and date a proxy card in the form to be filed by us on MAGNA on June 13, 2024 and attach to it a certificate signed by the TASE Clearing
House member through which the shares are held, which complies with the Israel Companies Regulations (Proof of Ownership for Voting in
General Meetings)-2000 as proof of ownership of the shares on the record date, and return the proxy card, along with the proof of ownership
certificate, to the offices of our attorneys, Doron Tikotzky Kantor Gutman & Amit Gross. (Attention: Ronen Kantor, Adv.) located at
7 Metsada St., B.S.R Tower 4, Bnei Brak, Israel, as described in the instructions available on MAGNA.
If you choose to attend the
Annual Meeting (where ballots will be provided), you must bring the proof of ownership certificate from the TASE’s Clearing House
member through which the shares are held, indicating that you were the beneficial owner of the shares on the record date.
Holders of ADSs
Under the terms of the Deposit
Agreement between the Company, The Bank of New York Mellon, as depositary, or BNY Mellon, and the holders of our ADSs, BNY Mellon shall
endeavor (insofar as is practicable) to vote or cause to be voted the number of shares represented by ADSs in accordance with the instructions
provided by the holders of ADSs to BNY Mellon. For ADSs that are held in “street name”, through a bank, broker or other nominee,
the voting process will be based on the underlying beneficial holder of the ADSs directing the bank, broker or other nominee to arrange
for BNY Mellon to vote the ordinary shares represented by the ADSs in accordance with the beneficial holder’s voting instructions.
If no instructions are received by BNY Mellon from any holder of ADSs (whether held directly by a beneficial holder or in “street
name”) with respect to any of the shares represented by the ADSs on or before the date established by BNY Mellon for such purpose,
BNY Mellon shall not vote or attempt to vote the shares represented by such ADSs.
Multiple Record Shareholders
or Accounts
You may receive more than
one set of voting materials, including multiple copies of this document and multiple proxy cards or voting instruction cards. For example,
shareholders who hold ADSs in more than one brokerage account will receive a separate voting instruction card for each brokerage account
in which ADSs are held. Shareholders of record whose shares are registered in more than one name will receive more than one proxy card.
You should complete, sign, date and return each proxy card and voting instruction card you receive.
Our Board of Directors urges
you to vote your shares so that they will be counted at the Annual Meeting or at any postponements or adjournments of the Annual Meeting.
Solicitation of Proxies
By appointing “proxies”,
shareholders and ADS holders may vote at the Annual Meeting whether or not they attend. If a properly executed proxy in the attached form
is received by us at least 48 hours prior to the Annual Meeting (and received by BNY Mellon no later than the date indicated on the voting
instruction card, in the case of ADS holders), all of the shares represented by the proxy shall be voted as indicated on the form or,
if no preference is noted, shall be voted in favor of the matter described above, and in such manner as the holder of the proxy may determine
with respect to any other business as may come before the Annual Meeting or any adjournment thereof. Shareholders and ADS holders may
revoke their proxies at any time before the deadline for receipt of proxies by filing with us (in the case of holders of ordinary shares)
or with BNY Mellon (in the case of holders of ADSs), a written notice of revocation or duly executed proxy bearing a later date.
Proxies are being distributed
to shareholders and to ADS holders on or about June 13, 2024. Certain officers, directors, employees, and agents of ours, none of whom
will receive additional compensation therefor, may solicit proxies by telephone, emails, or other personal contact. We will bear the cost
for the solicitation of the proxies, including postage, printing, and handling, and will reimburse the reasonable expenses of brokerage
firms and others for forwarding material to beneficial owners of shares and ADSs.
To the extent you would like
to submit a position statement with respect to any of the Proposals described in this proxy statement pursuant to the Israeli Companies
Law 5759-1999 (the “Companies Law”), you may do so by delivery of appropriate notice to the offices of our attorneys,
Doron Tikotzky Kantor Gutman & Amit Gross. (Attention: Ronen Kantor, Adv.) located at 7 Metsada St., B.S.R Tower 4, Bnei Brak, Israel,
not later than ten days before the convening of the Annual Meeting. Response of the Board of Directors to the position statement may be
submitted not later than five days after the deadline for sending the position statement.
Quorum
At the close of business of
June 11, 2024, we had outstanding 544,906,149 ordinary shares, of which 290,048,900 were represented by ADSs. Each ordinary share (including
ordinary shares represented by ADSs) outstanding as of the close of business on the record date is entitled to one vote upon each of the
matters to be voted on at the Annual Meeting.
The quorum required to hold
the Annual Meeting consists of at least two shareholders present in person or by proxy who hold or represent between them at least one-third
of the voting rights in the Company. If the Meeting is adjourned for lack of a quorum it will be held on the same day in the following
week at the same time and place (with no need for any notice to the shareholders) or until such other later time if we serve notice to
the shareholders no less than seven days before the date fixed for the such adjourned Meeting (the “Deferred Meeting”).
If at a Deferred Meeting there is no quorum present half an hour after the time set for the Meeting, any number participating in the Deferred
Meeting shall represent a quorum and shall be entitled to discuss the matters set down on the agenda for the original Annual Meeting.
Vote Required for Each Proposal
Proposals 2, 3, 4, 5, 8, and
9 to be presented at the Annual Meeting require the affirmative vote of holders of at least a majority of the voting power represented
and voting on such proposal in person or by proxy on the matter presented for passage.
The approval of Proposals
6 and 7 is subject to the affirmative vote of the holders of a majority of the voting power represented and voting on such proposal in
person or by proxy. In addition, the shareholders’ approval must either include at least a majority of the ordinary shares voted
by shareholders who are not controlling shareholders nor are they shareholders who have a personal interest in the approval of the proposal
(excluding a personal interest that is not related to a relationship with the controlling shareholders), or the total ordinary shares
of noncontrolling shareholders and non-interested shareholders voted against the proposal must not represent more than 2% of the outstanding
ordinary shares.
Under the Israeli Companies
Law, in general, you will be deemed to be a controlling shareholder if you have the power to direct our activities, otherwise than by
reason of being a director or other office holder of ours, if you hold 25% or more of the voting rights in our Company or have the right
to appoint the majority of the directors of the Company or its chief executive officer, and you are deemed to have a personal interest
if any member of your immediate family or their spouse has a personal interest in the adoption of the proposal. In addition, you are deemed
to have a personal interest if a company, other than XTL, that is affiliated to you has a personal interest in the adoption of the proposal.
Such company is a company in which you or a member of your immediate family serves as a director or chief executive officer, has the right
to appoint a director or the chief executive officer, or owns 5% or more of the outstanding shares. However, you are not deemed to have
a personal interest in the adoption of the proposal if your interest in such proposal arises solely from your ownership of our shares,
or to a matter that is not related to a relationship with a controlling shareholder.
In the proxy card and voting
instruction card attached to the proxy statement you will be asked to indicate whether you have a personal interest with respect to the
proposal. If any shareholder casting a vote in connection hereto does not notify us whether or not they have a personal interest with
respect to the proposal, their vote with respect to the proposal will be disqualified.
If you provide specific instructions
(mark boxes) with regard to certain Proposals, your shares will be voted as you instruct. If you sign and return your proxy card or voting
instruction form without giving specific instructions, your shares will be voted in accordance with the recommendations of our Board of
Directors. The proxy holders will vote in their discretion on any other matters that properly come before the Annual Meeting.
If you are a shareholder of
record and do not return your proxy card, your shares will not be voted. If you hold shares (or ADSs representing shares) beneficially
in street name, your shares will also not be voted at the Annual Meeting if you do not return your proxy card or voting instruction card
to instruct your broker or BNY Mellon how to vote. For all proposals, a broker (and BNY Mellon) may only vote in accordance with instructions
from a beneficial owner of shares or ADSs. This will be true even for a routine matter, such as Proposal 2 (the approval of the re-appointment
of our independent registered public accounting firm and authorization of our Board of Directors to fix such accounting firm’s annual
compensation), as your broker and BNY Mellon will not be permitted to vote your shares in their discretion on any proposal at the Annual
Meeting. For all proposals, a broker (and BNY Mellon) may only vote in accordance with instructions from a beneficial owner of shares
or ADSs.
Availability of Proxy Materials
Copies of the proxy card and
voting instruction card, the Notice of the Annual Meeting and this Proxy Statement are available at the “Investor Information”
portion of our website, http://www.xtlbio.com/. The contents of that website are not a part of this Proxy Statement.
Reporting Requirements
We are subject to the information
reporting requirements of the Securities Exchange Act of 1934, as amended, or Exchange Act, applicable to foreign private issuers. We
fulfill these requirements by filing reports with the Securities and Exchange Commission (the “Commission”). Our filings
with the Commission may be inspected without charge at the Commission’s Public Reference Room at 100 F Street, N.E., Washington,
D.C. 20549. Information on the operation of the Public Reference Room can be obtained by calling the Commission at 1-800-SEC-0330. Our
filings are also available to the public on the Commission’s website at http://www.sec.gov.
As a foreign private issuer,
we are exempt from the rules under the Securities Exchange Act, or Exchange Act of 1934, as amended, related to the furnishing and content
of proxy statements. The circulation of this notice and proxy statement should not be taken as an admission that we are subject to the
proxy rules under the Exchange Act.
PROPOSAL 1:
REVIEW AND DISCUSSION OF AUDITOR’S REPORT
AND CONSOLIDATED FINANCIAL STATEMENTS
At the Annual Meeting, in
accordance with the requirements of the Companies Law, our auditor’s report, annual report and consolidated financial statements
for the year ended as of December 31, 2023 will be presented. We will furthermore hold a discussion with respect to such financial statements
at the Annual Meeting. This item will not involve a vote of the shareholders.
The
foregoing auditor’s report and the audited consolidated financial statements, as well as our Annual Report on Form 20-F for the
year ended as of December 31, 2023 (filed with the Securities and Exchange Commission on April 30, 2024), may be reviewed at through the
EDGAR website of the Securities and Exchange Commission at www.sec.gov, through the Israeli Securities Authority’s electronic filing
system at: http://www.magna.isa.gov.il, or through the website of the Tel-Aviv Stock Exchange Ltd. at: http://maya.tase.co.il. None of
the auditor’s report, audited consolidated financial statements, Form 20-F and its amendments or the contents of our website form
part of the proxy solicitation material.
PROPOSAL 2:
APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTANTS AND
AUTHORIZATION OF THE BOARD, UPON THE RECOMMENDATION
OF THE AUDIT COMMITTEE, TO DETERMINE THE AUDITORS’ REMUNERATION TO BE FIXED IN ACCORDANCE WITH THE VOLUME AND NATURE OF THEIR SERVICES
TO THE COMPANY FOR SUCH FISCAL YEAR
Background
It is proposed to re-appoint
Somekh Chaikin, Certified Public Accountants in Israel and a member firm of KPMG as the Company’s independent auditors (the “Proposed
Auditors”) for the fiscal year ending December 31, 2024, until our next annual general Meeting of shareholders and to authorize
our Board of Directors, upon recommendation of the Audit Committee to determine KPMG’s remuneration to be fixed in accordance with
the volume and nature of their services to the Company for such fiscal year.
The following table sets forth
for the year ended 2023, the fees billed by the Company’s independent registered public firm.
| Service
Rendered | |
Year
ended December 31, 2023 | |
| Audit (1) | |
US$ |
80,000 | |
| Audit related services (2) | |
| |
| Tax | |
US$ |
5,000 | |
| All other fees | |
| |
| Total | |
US$ |
85,000 | |
| (1) | Audit fees consist of services that would normally be provided
in connection with statutory and regulatory filings or engagements, including services that generally only the independent accountant
can reasonably provide. |
| (2) | Audit related services consist of services that were reasonably
related to the performance of the audit or reviews of our financial statements and not included under “Audit Fees” above,
including, principally, providing consents for registration statement filings. |
Proposed Resolution
It is proposed that at the
Annual Meeting the following resolution shall be adopted:
“RESOLVED, that the
appointment of Somekh Chaikin, Certified Public Accountants in Israel and a member firm of KPMG, as the Company’s independent auditors
for the fiscal year ending December 31, 2024, until our next annual general Meeting of shareholders and the same hereby is, approved,
and that the Company’s Board of Directors be, and the same hereby is, authorized, subject to the approval of the Audit Committee,
to determine their fees, as presented to the shareholders, be and the same hereby are, approved.”
Required Vote
Under the Israeli Companies
Law, the affirmative vote of the holders of a majority of the voting power represented and voting on this Proposal in person or by proxy
is necessary to approve the resolution to approve the appointment of our independent auditors and authorize the Audit Committee to fix
the independent auditors’ renumeration.
Board Recommendation
Our Board of Directors recommends
a vote FOR the foregoing resolution approving the appointment of our independent auditors and authorization of our Audit Committee or
Board of Directors to fix the independent auditors’ compensation.
PROPOSALS 3-5:
RE-ELECTION OF DIRECTORS
Background
Under the Companies Law and
our articles of association, the management of our business is vested in our Board of Directors. The Board of Directors may exercise all
powers and may take all actions that are not specifically granted to our shareholders.
Our Board of Directors currently
consists of seven directors, including two external directors. Our directors, excluding the external directors, are elected at each annual
general meeting of shareholders. All of the members of our Board of Directors, other than the external directors, may be re-elected for
an unlimited number of terms upon completion of their then-current term of office.
Each of the nominees, whose
professional background is provided below, has advised us that he or she are willing, able and ready to serve as a director if elected
or re-elected as the case may be.
Alexander Rabinovich
joined our Board of Directors in April 2017. He has significant public company experience with both NASDAQ and TASE listed companies.
Mr. Rabinovich is currently the Chief Executive Officer and director of Green Forest Holdings Ltd., a fully owned company engaged in capital
investments and of Intercure Ltd. (TASE, NASDAQ) In addition, he serves as a director and CEO of Green Fileds Capital Ltd. (TASE). Mr.
Rabinovich served as director in Pilat Media Global PLC, public company listed on TASE and on the Alternative Investment Market of the
London Stock Exchange and several other private companies such as Visuality Systems Ltd. Mr. Rabinovich holds a B.A. degree in Economics
and Accounting from the University of Haifa.
Shlomo Shalev joined
our Board of Directors in December 2014 and in August 2015 was appointed to serve as Chairman and served in such capacity until July 2018
and currently serves as the Company CEO. He most recently served as Chairman of the board of directors at Intercure and Micronet, both
TASE listed companies. In addition to serving as a Board member on a number of NASDAQ and TASE listed companies, such as Ophir Optronics,
Arel Communications and PowerDsine, Mr. Shalev was the Senior Vice President of Investments for Ampal. He has also worked on a number
of transactions in mergers and acquisitions and initial public offerings. With an educational background in economics, Mr. Shalev was
Israel’s Consul for Economic Affairs and the Economic Advisor to the Director General, Ministry of Industry and Trade. Mr. Shalev
holds an MBA from the University of San Francisco and a B.A. degree in Economics from the University of Ben Gurion, Beer Sheva, Israel.
Doron Turgeman joined
our Board of Directors in December 2014 and currently serve as Chairman. He has significant public company experience with both NASDAQ
and TASE listed companies. Mr. Turgeman is currently the Chief Executive Officer of Internet Gold (IGLD), and since 2011 until January
2019 also used to be the CEO of B Communications (BCOM), both of which are listed on the NASDAQ. Mr. Turgeman has gained considerable
experience in mergers and acquisitions involving both debt and equity, with, among other things, the purchase of the controlling interest
of Bezeq by B Communications. He is knowledgeable in capital markets in Israel, the U.S. and Europe as well as SEC and TASE reporting
standards. Mr. Turgeman holds a B.A. degree in Economics and Accounting from the Hebrew University of Jerusalem and is a certified public
accountant in Israel.
Proposed Resolutions
It is proposed that at the
Annual Meeting the following resolutions shall be adopted:
“RESOLVED, that the
re-election of Alexander Rabinovitch as a director of the Company, to serve until our next annual general meeting of shareholders be,
and hereby is, approved in all respects.”
“RESOLVED, that the
re-election of Shlomo Shalev as a director of the Company, to serve until our next annual general meeting of shareholders be, and hereby
is, approved in all respects.”
“RESOLVED, that the
re-election of Doron Turgeman as a director of the Company, to serve until our next annual general meeting of shareholders be, and hereby
is, approved in all respects.”
Required Vote
Under the Companies Law and
our articles of association, the affirmative vote of the holders of a majority of the ordinary shares represented at the Annual Meeting,
in person or by proxy, entitled to vote and voting on the matter, is required to re-elect as directors each of the nominees named above.
Board Recommendation
Our Board of Directors recommends
a vote FOR the re-election of the foregoing director nominees.
It is hereby clarified that
resolutions approving the re-election of each director shall be adopted separately.
PROPOSALS 6-7
TRANSACTION
AGREEMENT TERMS AND CONDITIONS AND TRANSACTION CONSUMMATION
Background
On March 20, 2024 the Company
announced that it entered into a binding term sheet with Social Proxy an artificial intelligence web data company, developing and powering
a unique ethical, intellectual property based, proxy and data extraction platform for artificial intelligence and BI applications at scale,
to acquire all of the issued and outstanding share capital of the Social Proxy on a fully diluted basis, subject to the approval of shareholders
of the Company and receipt of necessary government approvals, if required.
On
June 5, 2024, the Company entered into that certain share purchase agreement with
the current shareholders of Social Proxy (the “Purchase Agreement”). Pursuant to the Purchase Agreement,
the Company will acquire all of the issued and outstanding share capital of Social Proxy on a fully diluted basis in exchange for (a)
the issuance by the Company to the shareholders of Social Proxy, by way of a private placement, such number of ADSs of the Company, representing
immediately after such issuance, 44.6% of the issued and outstanding share capital of the Company and (b) the payment of US$430,000 to
the shareholders of Social Proxy.
In addition, as part of the Transaction, the shareholders
of Social Proxy will be issued additional warrants, which may only be exercised upon reaching certain financial measured milestones (the
“Milestones”) within a period of up to three (3) years from the closing of the Transaction, Social Proxy will operate
as fully owned subsidiary of the Company and its shareholders will be entitled to appoint two (2) representatives to the Company’s
board of directors out of a total of up to seven (7) directors.
The Purchase Agreement contains
customary representations and warranties, agreements and obligations and conditions to closing, all as are customary for transactions
of this nature, including, without limitation, the approval of the Transaction by the Company’s shareholders and receipt of necessary
government or third-party approvals, if required.
The Purchase Agreement also
provides that at the closing, the Company shall provide Social Proxy with evidence that it retains a certain Minimum Equity of Cash (as
defined therein) and that until the earlier of (i) the lapse of a six (6) months period commencing as of the closing of the Transaction
and (ii) the date of achievement of the first Milestone, the ADS’s to be issued pursuant the Purchase Agreement shall be held in
escrow with an independent escrow agent. During the escrow period, current shareholders of the Social Proxy shall be entitled to exercise
all of the rights that the ADSs would entitle the holder of such ADSs in the capital of the Company, excluding the right to attend and
vote at a general meeting of the Company.
Proposed Resolutions
It is proposed that at the Annual Meeting the following
resolutions be adopted:
“RESOLVED, to approve the Purchase Agreement
and their execution by the Company.”
“RESOLVED, to approve the issuance of ordinary
shares pursuant to the Purchase Agreement, as the case may be.”
“RESOLVED, to authorize, empower and direct
the Chairman of the Board/Chief Executive Officer of the Company, in the name and on behalf of the Company, to take or cause to be taken
any and all such further actions he deems necessary to consummate the Transaction.”
Required Vote
The affirmative vote of the
holders of a majority of the voting power represented and voting on this proposal in person or by proxy is necessary for the approval
of the resolution to approve the re-election of the external director. In addition, the shareholders’ approval must either include
at least a majority of the ordinary shares voted by shareholders who are not controlling shareholders nor are they shareholders who have
a personal interest in the approval of the re-election of the external director, or the total ordinary shares of non-controlling shareholders
and non-interested shareholders voted against this proposal must not represent more than 2% of the outstanding ordinary shares.
For this purpose, you are
asked to indicate on your proxy card or voting instruction card whether you have a personal interest in the approval of the Purchase Agreement.
Under the Israeli Companies Law, in general, you are deemed to have a personal interest if any member of your immediate family or their
spouse has a personal interest in the adoption of the proposal. In addition, you are deemed to have a personal interest if a company,
other than the Company, that is affiliated to you has a personal interest in the adoption of the proposal. Such company is a company in
which you or a member of your immediate family serves as a director or chief executive officer, has the right to appoint a director or
the chief executive officer, or owns 5% or more of the outstanding shares. However, you are not deemed to have a personal interest in
the adoption of the proposal if your interest in such proposal arises solely from your ownership of our shares, or to a matter that is
not related to a relationship with a controlling shareholder.
Board Recommendation
Our Board of Directors recommends
a vote FOR the approval of the forgoing resolutions.
PROPOSALS 8-9
ELECTION, CONDITIONAL UPON
THE CONSUMMATION OF THE TRANSACTION, OF DIRECTORS
Background
Pursuant to the provisions
of the Transaction, the Board of Directors of the Company will consist, conditional upon the consummation of the Transaction, of seven
(7) directors, five (5) serving as directors and two (2) serving as external directors. Prior to the closing of the Transaction, Social
Proxy will be entitled to appoint two (2) representatives to the Company’s Board of Directors out of a total of up to seven (7)
directors.
Each of the nominees, whose
professional background is provided below, has advised us that he or she are willing, able and ready, conditional upon the consummation
of the Transaction, to serve as a director if elected. We do not have any understanding or agreement with respect to the future election
of any of the nominees named.
Tal Klinger
is founder and CEO of Social Proxy and its subsidiaries. Prior to his founding of Social Proxy, Mr. Klinger was the Co-Founder and CEO
of the Lychee Digital Group. Mr. Klinger has an extensive career as CEO and Director of start-up and technological companies around the
world. Mr. Klinger graduated from the College of Law and Business with a Masters In international commercial transactions and bachelor
degrees in both Law and Administration and Management.
Yair Redl
was a partner and CEO at Deloitte and served as a senior manager and chief financial officer at several technology companies throughout
the years. Currently he is founder and Partner at A.Y. Augmented Management and a managing partner at Moore Management Consulting, while
serving as Chairman of the Board at Social Proxy and several other technology companies and startups. Mr. Redl graduated from Queens College
with a BA in Mathematics and Physics and from Columbia University with an MSc in operation research.
Proposed Resolutions
It is proposed that at the
Annual Meeting the following resolutions shall be adopted:
“RESOLVED, that, conditional
upon the consummation of the Transaction, the election of Tal Klinger as a director of the Company, to serve until our next annual general
meeting of shareholders be, and hereby is, approved in all respects.”
“RESOLVED, that, conditional
upon the consummation of the Transaction, the election of Yair Redl as a director of the Company, to serve until our next annual general
meeting of shareholders be, and hereby is, approved in all respects.”
Required Vote
Under the Companies Law and
our articles of association, the affirmative vote of the holders of a majority of the ordinary shares represented at the Annual Meeting,
in person or by proxy, entitled to vote and voting on the matter, is required to re-elect as directors each of the nominees named above.
Board Recommendation
Our Board of Directors recommends
a vote, conditional upon the consummation of the Transaction, FOR the election of the foregoing director nominees.
It is hereby clarified that
resolutions approving the election of each director shall be adopted separately.
OTHER BUSINESS
Other than as set forth above,
as of the mailing of this Proxy Statement, management knows of no business to be transacted at the Annual Meeting, but, if any other matters
are properly presented at the Annual Meeting, the persons named in the attached form of proxy will vote upon such matters in accordance
with their best judgment.
| |
By Order of the Board of Directors |
| |
|
| |
/s/ Shlomo Shalev |
| |
Shlomo Shalev
Chief Executive Officer |
| |
Dated: June 12, 2024 |
Annex A
To:
XTL BIOPHARMACEUTICALS LTD.
Declaration of Director’s Qualification
(Section 224(b) of the Israeli Companies’ Law -
1999 (the “Law”))
I, the undersigned, Alexander Rabinovich, I.D 014122568
hereby states, declares and undertakes to XTL BIOPHARMACEUTICALS Ltd. (the “Company”) as follows:
| 1. | I have the necessary qualifications and ability to devote
appropriate time to perform the position of a director in the Company, taking into account, among other things, the Company’s special
needs. |
| 2. | With accordance to paragraph 1 above, the following are details
regarding my skills: |
| 2.1 | Education-(Field of education, institution,
academic degree, certificate or professional license) |
B.A degree in Economics and Accounting from Haifa University
| 2.2 | Practice and Professional Experience- (Job description,
employer details, duration of service) |
February 2019 until today: CEO of Intercure Ltd.
2016 until today: CEO of Green Fields Capital Ltd.
2009 until today: CEO of Green Forest Holdings Ltd.
2013 until today: CEO of Green Forest Global
2009 until 2014: CEO of Eurocom Holdings and Investments Ltd.
& Eurocom Investments LP.
| 2.3 | Companies in which I serve or served as a director in the
past 5 years-(Job description, company’s name, duration of service) |
2018 until today: Intercure Ltd.
2018 until today: Canndoc Ltd.
2011 until today: Green Fields Capital Ltd.
2009 until today: Green Forest Holdings Ltd.
2013 until today: Green Forest Global
2013 until today: D.I.M Investments / D.I.M Risk
Management Ltd.
| 3. | I have not been convicted by a final judgment of one or more
offences specified under sections 290 to 297, 392, 415, 418 to 428 to the Israel Penal Law 5737-1997; or under sections 52C, 52D, 53(a)
and 54 to the Securities Law, 5728-1968 (“Securities Law”); and in any additional offences to those set forth above,
as prescribed by the Minister of Justice from time to time. |
| 4. | I have not been convicted by a final judgment in a court
outside of Israel for bribery, fraud, directors’ offenses involving misuse of inside information. |
| 5. | I have not been convicted by a final judgment of any other offense in which a court
determined that due to its nature, severely or circumstances I do not deserve the serve as director/director of a public company. |
| | | |
| 6. | I was not imposed by an administrative enforcement commission, appointed under
section 52(32)(a) of the Securities Law, with means of enforcement, as provided in section 52 of the Securities Law, or imposed under
Chapter H4 of the Securities Law, under Chapter G2 of the Regulation of Investment Counseling and Investment Portfolio Management Law,
1995 or under Chapter J1 to the Joint Investment Trust Law, 1994, as applicable. |
| | | |
| 7. | I am not a minor, incompetent, and was not declared insolvent. |
| | | |
| 8. | To this time, I maintain/do not maintain (Please delete the unnecessary) securities
of the company or of a subsidiary and/or related company of the company. |
Below are my stated Holdings:
| |
Quantity of | | |
The rate of Holdings | | |
The rate of Holdings (strong/full dilution) | |
| Name, type and series of Security | |
Securities | | |
Capital | | |
Vote | | |
Capital | | |
Vote | |
| ADR | |
| 661,394 | | |
| | | |
| | | |
| | | |
| | |
| Ordinary shares | |
| 62,149,487 | | |
| | | |
| | | |
| | | |
| | |
| Total: | |
| 128,288,887 | | |
| 23.54 | % | |
| 23.54 | % | |
| 22.31 | % | |
| 22.31 | % |
| 9. | I hereby declare that if any change shall apply in the above listed information
in a way that shall prevent the continuation of my service as director of the Company, I shall inform the company about the change immediately
and my service as a director shall terminate immediately. I am fully aware that the Company relied on the declaration of this statement
during the approval of my tenure as director of the Company. |
| 10. | I am aware that non-disclosure of information as mentioned above shall be considered
as a breach of my fiduciary duty to the Company. |
| 11. | I hereby declare that I shall meet all the law requirements regarding service as
a director of a public company, and serve for the benefit of the Company. |
| |
Signature: |
/s/ Alexander Rabinovich |
| |
|
|
| |
Date: June 6, 2024 |
To:
XTL
BIOPHARMACEUTICALS LTD.
Declaration of Director’s Qualification
(Section 224(b) of the Israeli Companies’ Law –
1999 (the “Law”))
I, the undersigned, Shlomo Shalev, I.D 057708422
hereby states, declares and undertakes to XTL BIOPHARMACEUTICALS Ltd. (the “Company”) as follows:
| 1. | I have the necessary qualifications and ability to devote appropriate time to perform the position of
a director in the Company, taking into account, among other things, the Company’s special needs. |
| 2. | With accordance to paragraph 1 above, the following are details regarding my skills: |
| 2.1 | Education- (Field of education, institution, academic degree, certificate or professional license) |
BA Ben Gurion University, Israel
MBA San Francisco University, CA USA
2.2. Practice and Professional Experience-
(Job description, employer details, duration of service)
Chairman
of the Board, GFC Green Fields Capital (TASE) 2015-Current
CEO GFC Green Fields Capital (TASE) 2014-2015
Active Chairman of the Board, Intercure
(TASE) 2015-2018
Active Chairman of the Board Micronet
(TASE) 2011-2013
Active Chairman of the Board NetformX
2007-2010
Senior VP Investments, Ampal (NASDAQ)
1998-2006
Consul for Economic Affairs, United States
Northwestern Region 1994-1998
Economic Advisor to the Director General,
Ministry of Industry and Trade
1992-1994
2.3. Companies in which I serve or
served as a Director in the past 5 years- (Job description, company’s name, duration of service)
GFC Green Fields Capital – 2015-current
Micronet 2017-2019
Intercure 2015-2018
Tigi Solar – 2021-Current
SaverOne – 2020 - Current
| 3. | I have not been convicted by a final judgment of one or more offences specified under sections 290 to
297, 392, 415, 418 to 428 to the Israel Penal Law 5737-1997; or under sections 52C, 52D, 53(a) and 54 to the Securities Law, 5728-1968
(“Securities Law”); and in any additional offences to those set forth above, as prescribed by the Minister of Justice
from time to time. |
| 4. | I have not been convicted by a final judgment in a court outside of Israel for bribery, fraud, directors’
offenses involving misuse of inside information. |
| 5. | I have not been convicted by a final judgment of any other offense in which a court determined that due
to its nature, severely or circumstances I do not deserve the serve as director/director of a public company. |
| 6. | I was not imposed by an administrative enforcement commission, appointed under section 52(32)(a) of the
Securities Law, with means of enforcement, as provided in section 52 of the Securities Law, or imposed under Chapter H4 of the Securities
Law, under Chapter G2 of the Regulation of Investment Counseling and Investment Portfolio Management Law, 1995 or under Chapter J1 to
the Joint Investment Trust Law, 1994, as applicable. |
| 7. | I am not a minor, incompetent, and was not declared insolvent. |
| 8. | To this time, I maintain/do not maintain (Please delete the unnecessary) securities of the company or
of a subsidiary and/or related company of the company. |
Below are my stated Holdings:
| |
Quantity of | | |
Treasury | | |
The rate of Holdings | | |
The rate of Holdings
(strong/full dilution) | |
| Name, type and series of Security | |
Securities | | |
Securities | | |
Capital | | |
Vote | | |
Capital | | |
Vote | |
| Shares | |
| 3,019,309 | | |
| | | |
| | | |
| | | |
| | | |
| | |
| 9. | I hereby declare that if any change shall apply in the above listed information in a way that shall prevent
the continuation of my service as director of the Company, I shall inform the company about the change immediately and my service as a
director shall terminate immediately. I am fully aware that the Company relied on the declaration of this statement during the approval
of my tenure as director of the Company. |
| 10. | I am aware that non-disclosure of information as mentioned above shall be considered as a breach of my
fiduciary duty to the Company. |
| 11. | I hereby declare that I shall meet all the law requirements regarding service as a director of a public
company, and serve for the benefit of the Company. |
| |
Signature: |
/s/ Shlomo Shalev |
| |
|
| |
Date: June 5, 2024 |
To:
XTL
BIOPHARMACEUTICALS LTD.
Declaration of Director’s Qualification
(Section 224(b) of the Israeli Companies’ Law –
1999 (the “Law”))
I, the undersigned, Doron Turgeman, I.D
023568389 hereby states, declares and undertakes to XTL BIOPHARMACEUTICALS Ltd. (the “company”) as follows:
| 1. | I have the necessary qualifications and ability to devote appropriate time to perform the position of a director
in the Company, taking into account, among other things, the Company’s special needs. |
| 2. | With
accordance to paragraph
1 above, the following are details regarding my skills: |
| 2.1 | Education-(Field
of education, institution, academic degree, certificate or professional) |
B.A.
Economics and Accounting. Hebrew University of Jerusalem, Israel
| 2.2. | Practice
and Professional Experience-(Job description, employer details, duration of service) |
Since
2020 : Independent financial advisor that provide management services, debts restructuring consulting, and board services
to public companies in Israel. Currently serves as board member at 6 public companies which trade on TASE.
October 2011 - February 2021
(10 years): CEO of Internet Gold which is publicly-traded company dual-listed on Nasdaq and TASE.
From October 2011 until January
2019 I served in addition, as CEO of B Communications which is publicly-traded company dual-listed on Nasdaq and TASE.
2008-October 2011 (3 years):
Deputy CEO and CFO, Internet Gold. In tandem, VP of Eurocom Panasonic, the sole distributer of Panasonic in Israel and CFO of Eurocom
Communications between 2012-2015.
| 2.3. | Companies
in which I serve or served as a Director in the past 5 years- (Job description, company’s
name, duration of service) |
Since
November 2021: Board member of Effi Capital real estate, a public company which trade on TASE.
Since October 2019: Board member of
Alon Ribua Kahol, one of the largest Israeli holding companies.
Since February 2016: Board member
of The Klein International Group Limited, BVI company which raised bonds on TASE.
Since June 2020: Board member of M.V
Investments, Israeli real estate company which raised bonds on TASE.
Since September 2020: Board member
of Encore Group Limited, BVI company which raised bonds on TASE.
Between February 2018 until December
2019: Board member of BEZEQ, the largest Israeli telecoms company.
Between November 2021 until September
2022: Board member of Erica Carmel, which trade on TASE.
| 3. | I have not been convicted by a final judgment of one or more offences specified under sections 290 to
297, 392, 415, 418 to 428 to the Israel Penal Law 5737-1997; or under sections 52C, 52D, 53(a) and 54 to the Securities Law, 5728-1968
(“Securities Law”); and in any additional offences to those set forth above, as prescribed by the Minister of Justice
from time to time. |
| 4. | I have not been convicted by a final judgment in a court outside of Israel for bribery, fraud, directors’
offenses involving misuse of inside information. |
| 5. | I have not been convicted by a final judgment of any other offense in which a court determined that due
to its nature, severely or circumstances I do not deserve the serve as director/director of a public company. |
| 6. | I was not imposed by an administrative enforcement commission, appointed under section 52(32)(a) of the
Securities Law, with means of enforcement , as provided in section 52 of the Securities Law, or imposed under Chapter H4 of the Securities
Law, under Chapter G2 of the Regulation of Investment Counseling and Investment Portfolio Management Law, 1995 or under Chapter J1 to
the Joint Investment Trust Law, 1994, as applicable. |
| 7. | I am not a minor, incompetent, and was not declared insolvent. |
| 8. | To this time, I maintain/do not maintain (Please delete the unnecessary) securities of the company or
of a subsidiary and/or related company of the company. |
Below are my stated Holdings:
| Name, type and | |
No. of
Security on
the stock | | |
Quantity of | | |
Treasury | | |
The rate of Holdings | | |
The rate of Holdings (strong/full dilution) | |
| series of Security | |
exchange | | |
Securities | | |
Securities | | |
Capital | | |
Vote | | |
Capital | | |
Vote | |
| XTL ADR | |
| 3,400 | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| 9. | I hereby declare that if any change shall apply in the above listed information in a way that shall prevent
the continuation of my service as director of the Company, I shall inform the company about the change immediately and my service as a
director shall terminate immediately. I am fully aware that the Company relied on the declaration of this statement during the approval
of my tenure as director of the Company. |
| 10. | I am aware that non-disclosure of information as mentioned above shall be considered as a breach of my
fiduciary duty to the Company. |
| 11. | I hereby declare that I shall meet all the law requirements regarding service as a director of a public
company, and serve for the benefit of the Company. |
| |
Signature: |
/s/ Doron Turgeman |
| |
|
|
| |
Date: June 5, 2024 |
Annex B
To:
XTL
BIOPHARMACEUTICALS LTD.
Declaration
of Director’s Qualification
(Section
224(b) of the Israeli Companies’ Law – 1999 (the “Law”))
I,
the undersigned, Tal Klinger, I.D 204008411 hereby states, declares and undertakes to XTL BIOPHARMACEUTICALS Ltd. (the
“Company”) as follows:
| 1. | I
have the necessary qualifications and ability to devote appropriate time to perform the position
of a director in the Company, taking into account, among other things, the Company’s special
needs. |
| 2. | With
accordance to paragraph 1 above, the following are details regarding my skills: |
| 2.1 | Education-
(Field of education, institution, academic degree, certificate or professional license) |
| ● | Master
of Laws – LLM, Specialty in international l commercial transaction from College of
Law and Business. |
| ● | Bachelor
of Laws – LLB, Law specialty in Commercial Law from College of Law and Business. |
| ● | Bachelor
Degree Business Administration and Management from College of Law and Business. |
| 2.2. | Practice
and Professional Experience-(Job description, employer details, duration of service) |
| ● | March
2023 until today: Manager, ALIGN TECHNOLOGIES AND DATA, UNIPESSOAL LDA. |
| ● | January
2020 until today: CEO, director and founder, “The Social Proxy Ltd”. |
| ● | April
2021 until today: CEO, director and president. “The Social Proxy Inc.” |
| ● | June
2019 until June 2021: Co-Founder and CEO at Lychee, Lychee Digital Group. |
| ● | April
2019 until September 2020: Growth Hacker, Adecco Middle East. |
| 2.3. | Companies in
which I serve or served as a Director in the past 5 years-(Job description, company’s name, duration of service) |
| ● | January
2020 until today: Director, The Social Proxy Ltd. |
| ● | April
2021 until today: Director, The Social Proxy Inc. |
| 3. | I
have not been convicted by a final judgment of one or more offences specified under sections
290 to 297, 392, 415, 418 to 428 to the Israel Penal Law 5737-1997; or under sections 52C,
52D, 53(a) and 54 to the Securities Law, 5728-1968 (“Securities Law”); and
in any additional offences to those set forth above, as prescribed by the Minister of Justice
from time to time. |
| 4. | I
have not been convicted by a final judgment in a court outside of Israel for bribery,
fraud, directors’ offenses involving misuse of inside information. |
| 5. | I
have not been convicted by a final judgment of any other offense in which a court determined
that due to its nature, severely or circumstances I do not deserve the serve as director/director
of a public company. |
| 6. | I
was not imposed by an administrative enforcement commission, appointed under section 52(32)(a)
of the Securities Law, with means of enforcement, as provided in section 52 of the Securities
Law, or imposed under Chapter H4 of the Securities Law, under Chapter G2 of the Regulation
of Investment Counseling and Investment Portfolio Management Law, 1995 or under Chapter J1
to the Joint Investment Trust Law, 1994, as applicable. |
| 7. | I
am not a minor, incompetent, and was not declared insolvent. |
| 8. | To
this time, I do not maintain securities of the company or of a subsidiary and/or related
company of the company. |
Below
are my stated Holdings:
| Name, type and series of | |
No. of
Security on the stock | |
| |
Treasury | |
The rate of Holdings | | |
The rate of Holdings (strong/full dilution) | |
| Security | |
exchange | |
Quantity of Securities | |
Securities | |
Capital | | |
Vote | | |
Capital | | |
Vote | |
| Shares | |
| |
Upon the consummation of the Transaction as detailed in Company’s Form 6-K, dated June 5, 2024, 258,687,265 represented by 2,586,873 ADS of the Company, | |
| |
| | | |
| | | |
| | | |
| | |
| 9. | I
hereby declare that if any change shall apply in the above listed information in a way that
shall prevent the continuation of my service as director of the Company, I shall inform the
company about the change immediately and my service as a director shall terminate immediately.
I am fully aware that the Company relied on the declaration of this statement during the
approval of my tenure as director of the Company. |
| 10. | I
am aware that non-disclosure of information as mentioned above shall be considered as a breach
of my fiduciary duty to the Company. |
| 11. | I
hereby declare that I shall meet all the law requirements regarding service as a director
of a public company, and serve for the benefit of the Company. |
| |
Signature: |
/s/ Tal Klinger |
| |
|
| |
Date: June 11, 2024 |
To:
XTL
BIOPHARMACEUTICALS LTD.
Declaration
of Director’s Qualification
(Section
224(b) of the Israeli Companies’ Law – 1999 (the “Law”))
I,
the undersigned, Yair Redl, Israeli I.D No. 0-5828652-7hereby states, declares and undertakes to XTL BIOPHARMACEUTICALS Ltd.
(the “Company”) as follows:
| 1. | I
have the necessary qualifications and ability to devote appropriate time to perform the position
of a director in the Company, taking into account, among other things, the Company’s special
needs. |
| 2. | With
accordance to paragraph 1 above, the following are details regarding my skills: |
BA
degree in Mathematics, minor Physics from Queens College
MSc
– operation research from Columbia University
| 2.2. | Practice
and Professional Experience-(Job description, employer details, duration of service) |
| ● | January
2019 until today: Managing Partner, owner, “Moore Management Consulting”. |
| ● | January
2023 until today: Chairman of the Board, “NRN Norm”. |
| ● | January
2022 until today: Chief financial officer and Chairman of the Board, “The Social Proxy
Ltd”. |
| ● | January
2019 until today: Chairman of the Board, “A.Y.Mavlet Technologies”. |
| ● | May
2008 until December 2018: Managing partner, “ICG -Integra Consulting Group”. |
| ● | June
2003 until December 2004: Director of immigration (Aliyah) Division at “The Jew Agency
for Israel” |
| ● | March
2003 until October 2005: Partner & CEO, Deloitte. |
| ● | March
2003 until October 2005: CIO, Director of Recovery Process, “Leumit Health Fund (HMO). |
| 2.3. | Companies
in which I serve or served as a Director in the past 5 years-(Job description, company’s
name, duration of service) |
| ● | January
2023 until today: Chairman of the Board - NRN Norm. |
| ● | January
2022 until today: Director - The Social Proxy Ltd. |
| ● | January
2024 until today: Director -The Social Proxy Inc. |
| 3. | I
have not been convicted by a final judgment of one or more offences specified under sections
290 to 297, 392, 415, 418 to 428 to the Israel Penal Law 5737-1997; or under sections 52C,
52D, 53(a) and 54 to the Securities Law, 5728-1968 (“Securities Law”); and
in any additional offences to those set forth above, as prescribed by the Minister of Justice
from time to time. |
| 4. | I
have not been convicted by a final judgment in a court outside of Israel for bribery,
fraud, directors’ offenses involving misuse of inside information. |
| 5. | I
have not been convicted by a final judgment of any other offense in which a court determined
that due to its nature, severely or circumstances I do not deserve the serve as director/director
of a public company. |
| 6. | I
was not imposed by an administrative enforcement commission, appointed under section 52(32)(a)
of the Securities Law, with means of enforcement, as provided in section 52 of the Securities
Law, or imposed under Chapter H4 of the Securities Law, under Chapter G2 of the Regulation
of Investment Counseling and Investment Portfolio Management Law, 1995 or under Chapter J1
to the Joint Investment Trust Law, 1994, as applicable. |
| 7. | I
am not a minor, incompetent, and was not declared insolvent. |
| 8. | To
this time, I do not maintain securities of the company or of a subsidiary and/or related
company of the Company. |
Below
are my stated Holdings:
| Name, type and series of | |
No. of
Security on the stock | |
| |
Treasury | |
The rate of Holdings | | |
The rate of Holdings (strong/full dilution) | |
| Security | |
exchange | |
Quantity of Securities | |
Securities | |
Capital | | |
Vote | | |
Capital | | |
Vote | |
| Shares | |
| |
Upon the consummation of the Transaction as detailed in Company’s Form 6-Kk dated June 5, 2024, 28,041,700 represented by 280,417 ADS of the Company, indirectly through A.Y Augmented Management | |
| |
| | | |
| | | |
| | | |
| | |
| 9. | I
hereby declare that if any change shall apply in the above listed information in a way that
shall prevent the continuation of my service as director of the Company, I shall inform the
company about the change immediately and my service as a director shall terminate immediately.
I am fully aware that the Company relied on the declaration of this statement during the
approval of my tenure as director of the Company. |
| 10. | I
am aware that non-disclosure of information as mentioned above shall be considered as a breach
of my fiduciary duty to the Company. |
| 11. | I
hereby declare that I shall meet all the law requirements regarding service as a director
of a public company, and serve for the benefit of the Company. |
| |
Signature: |
/s/ Yair Redl |
| |
|
| |
Date: June 11, 2024 |
B-4
Exhibit 99.2
XTL Biopharmaceuticals Ltd.
PROXY FOR THE ANNUAL AND EXTRAORDINARY GENERAL
MEETING OF SHAREHOLDERS
TO BE HELD ON JULY 22, 2024
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD
OF DIRECTORS.
The undersigned hereby appoints
Shlomo Shalev, Chief Executive Officer, attorney, agent and proxy of the undersigned, with full power of substitution to each of them,
to represent and to vote on behalf of the undersigned all the ordinary shares in XTL Biopharmaceuticals Ltd. (the “Company”)
which the undersigned is entitled to vote at the annual and extraordinary general meeting of shareholders (the “Annual Meeting”)
to be held at the offices of the Company’s attorneys, Doron Tikotzky Kantor Gutman & Amit Gross., at 7 Metsada St., B.S.R Tower
4, Bnei Brak, Israel, on July 22, 2024 at 15:00 PM (Israel time), and at any adjournments or postponements thereof, upon the following
matters, which are more fully described in the Notice of Annual and Extraordinary General Meeting of Shareholders (the “Notice”)
and proxy statement relating to the Annual Meeting (the “Proxy Statement”).
The undersigned acknowledges
receipt of the Notice and Proxy Statement of the Company relating to the Annual Meeting. All terms that are not defined in this Proxy
shall have the same meaning of such terms in the Notice and/or the Proxy Statement.
This Proxy, when properly
executed, will be voted in the manner directed herein by the undersigned. If no direction is made with respect to any matter, this Proxy
will be voted FOR such matter. Any and all proxies heretofore given by the undersigned are hereby revoked.
(Continued and to be signed on the reverse side)
ANNUAL AND EXTRAORDINARY GENERAL MEETING OF
SHAREHOLDERS OF
XTL BIOPHARMACEUTICALS LTD.
July 22, 2024, 15:00 p.m. (Israel time)
Please date, sign and mail
your proxy card in the
envelope provided as soon
as possible.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR”
EACH OF THE PROPOSALS FOR THE MEETING
PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE
ENCLOSED ENVELOPE.
PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS
SHOWN HERE ☒
| 1. | To
appoint Somekh Chaikin, Certified Public Accountants in Israel and a member firm of KPMG as the Company’s independent auditors
for the fiscal year ending December 31, 2023. |
| |
☐ |
for |
☐ |
against |
☐ |
abstain |
| 2. | To
re-elect Alexander Rabinovitch to the Company’s Board of Directors for a term expiring at the Company’s next annual general
meeting of shareholders. |
| |
☐ |
for |
☐ |
against |
☐ |
abstain |
| 3. | To
re-elect Shlomo Shalev to the Company’s Board of Directors for a term expiring at the Company’s next annual general meeting
of shareholders. |
| |
☐ |
for |
☐ |
against |
☐ |
abstain |
| 4. | To
re-elect Doron Turgeman to the Company’s Board of Directors for a term expiring at the Company’s next annual general meeting
of shareholders. |
| |
☐ |
for |
☐ |
against |
☐ |
abstain |
| 5. | To
approve the terms and provisions of the acquisition of The Social Proxy Ltd. (“Social Proxy”), as more fully detailed
in the Company’s Form 6-K dated June 5, 2024 (the “Transaction”) which includes (a) the issuance to the shareholders
of Social Proxy such number of ADS’s of the Company which represent 44.6% of the issued and outstanding share capital of the Company
and (b) the payment of US$430,000 in cash to the shareholders of Social Proxy. |
| |
☐ |
for |
☐ |
against |
☐ |
abstain |
Are you a controlling shareholder of the
Company, or do you have a personal interest in the approval of terms and provisions of the Transaction, other than a personal interest
unrelated to relationships with a controlling shareholder of the Company? Please note: If you do not mark either Yes or No, your shares
will not be voted for this proposal.
| 6. | To
approve the consummation of the Transaction by the Company and to authorize, empower and direct Chief Executive Officer of the Company,
in the name and on behalf of the Company, to take or cause to be taken any and all such further actions and to prepare, execute, deliver
and file, or cause to be prepared, executed, delivered and filed any documents and such other reports, schedules, statements, consents,
documents, agreements, certificates, undertakings in the name of and on behalf of the Company as he shall in his judgment, with the advice
of counsel, determine to be necessary, proper or desirable to carry out fully the intent and purposes of the foregoing resolutions in
order to consummate the transactions contemplated by the Transaction (the “Consummation”). |
| |
☐ |
for |
☐ |
against |
☐ |
abstain |
Are you a controlling shareholder of the
Company, or do you have a personal interest in the approval of Consummation of the Transaction, other than a personal interest unrelated
to relationships with a controlling shareholder of the Company? Please note: If you do not mark either Yes or No, your shares will
not be voted for this proposal.
| 7. | To
elect, conditional upon the Consummation of the Transaction, Tal Klinger to the Company’s Board of Directors for a term expiring
at the Company’s next annual general meeting of shareholders. |
| |
☐ |
for |
☐ |
against |
☐ |
abstain |
| 8. | To
elect, conditional upon the Consummation of the Transaction, Yair Redl to the Company’s Board of Directors for a term expiring
at the Company’s next annual general meeting of shareholders. |
|
|
☐ |
for |
☐ |
against |
☐ |
abstain |
In their discretion, the proxies
are authorized to vote upon such other matters as may properly come before the Annual Meeting or any adjournment or postponement thereof.
| |
|
Date: ________, 2024 |
|
|
|
Date_________, 2024 |
| SIGNATURE |
|
|
|
SIGNATURE |
|
|
Please sign exactly as your name appears on this
Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, trustee or guardian, please give
full title as such. If the signed is a corporation, please sign full corporate name by duly authorized officer, giving full title as such.
If signer is a partnership, please sign in partnership name by authorized person.
Exhibit 99.3
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
Von Nov 2023 bis Nov 2024
